OpenLB
Open Library of Bioscience
Advanced Search
Cellular & molecular immunology
Oct, 2004;1 (5): 357-66.

Global gene expression profiling in interleukin-12-induced activation of CD8(+) cytotoxic T lymphocytes against mouse mammary Carcinoma.

Shanjin Cao, Zhaoying Xiang, Xiaojing Ma
Author Information
  1. Shanjin Cao: Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York 10021, USA.
PMID: 16285895

Abstract

Interleukin-12 (IL-12) is a critical cytokine representing the link between the cellular and humoral branches of host immune defense apparatus. IL-12-induced cytotoxic lymphocyte (CTL) development is a central mechanism in immune responses against intracellular infectious agents as well as malignant growth. However, the molecular basis of tumor-specific CTL responses mediated by IL-12 remains poorly defined. In this study, we addressed this issue in a comprehensive manner to probe into IL-12-induced anti-tumor responses by global gene expression profiling of mRNA expression in CD8(+) T cells in a transplantable syngeneic mouse mammary carcinoma model treated or not with recombinant IL-12. A strong tumor regression was induced by the IL-12 treatment. An introspection of differential gene expression at an early stage of the IL-12-initiated CTL activation reveals interesting genes and molecular pathways that may account for the marked tumor regression, and is likely to provide a rich source of potential targets for further research and development of effective therapeutic modalities.

References

  1. Gene Ther. 2002 Jun;9(12):793-803 [PMID: 12040461]
  2. Immunol Today. 1997 Jun;18(6):267-8 [PMID: 9190110]
  3. J Natl Cancer Inst. 1997 Jul 16;89(14):1049-58 [PMID: 9230887]
  4. Biochem Mol Med. 1997 Aug;61(2):127-35 [PMID: 9259977]
  5. Clin Exp Metastasis. 1983 Oct-Dec;1(4):373-80 [PMID: 6546207]
  6. Biochim Biophys Acta. 1986 Dec 17;865(3):289-305 [PMID: 3539199]
  7. Mol Cell Biol. 1990 Aug;10(8):4116-22 [PMID: 2115118]
  8. Adv Immunol. 1991;49:281-355 [PMID: 1853786]
  9. Int J Cancer. 1991 Aug 19;49(1):44-9 [PMID: 1678734]
  10. Genes Dev. 1992 Mar;6(3):481-96 [PMID: 1547944]
  11. Genomics. 1992 Aug;13(4):1008-17 [PMID: 1380482]
  12. Curr Opin Immunol. 1992 Oct;4(5):603-7 [PMID: 1418726]
  13. Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2591-9 [PMID: 10937571]
  14. Blood. 2001 Jan 1;97(1):192-7 [PMID: 11133760]
  15. Mol Cell Biol. 2001 Feb;21(4):1370-83 [PMID: 11158322]
  16. Int J Cancer. 2001 Nov 1;94(3):390-5 [PMID: 11745419]
  17. Lung Cancer. 2002 Apr;36(1):17-25 [PMID: 11891029]
  18. Blood. 2002 Apr 1;99(7):2512-7 [PMID: 11895787]
  19. Cytokine Growth Factor Rev. 2002 Apr;13(2):95-109 [PMID: 11900986]
  20. Mol Ther. 2002 May;5(5 Pt 1):609-16 [PMID: 11991752]
  21. Oncogene. 1994 May;9(5):1397-406 [PMID: 8152800]
  22. Mol Cell Biol. 1994 May;14(5):3459-68 [PMID: 7513052]
  23. J Biol Chem. 1994 May 13;269(19):14191-8 [PMID: 8188702]
  24. Int J Cancer. 1994 Aug 1;58(3):317-23 [PMID: 7914181]
  25. J Biol Chem. 1994 Sep 30;269(39):23865-8 [PMID: 7929030]
  26. Immunity. 1994 Sep;1(6):447-56 [PMID: 7895156]
  27. Oncogene. 1995 Apr 6;10(7):1461-3 [PMID: 7731700]
  28. J Biol Chem. 1995 Jun 16;270(24):14801-8 [PMID: 7782346]
  29. Science. 1997 Oct 24;278(5338):680-6 [PMID: 9381177]
  30. Int J Biochem Cell Biol. 1997 Dec;29(12):1371-87 [PMID: 9570133]
  31. Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61 [PMID: 9636188]
  32. Immunity. 1998 Jul;9(1):25-34 [PMID: 9697833]
  33. J Biol Chem. 1998 Aug 28;273(35):22161-4 [PMID: 9712825]
  34. Cancer Res. 1998 Aug 15;58(16):3491-4 [PMID: 9721846]
  35. Adv Immunol. 1998;70:83-243 [PMID: 9755338]
  36. J Exp Med. 1998 Nov 2;188(9):1657-68 [PMID: 9802978]
  37. Curr Top Microbiol Immunol. 1999;238:57-78 [PMID: 10087650]
  38. J Exp Clin Cancer Res. 1999 Jun;18(2):191-200 [PMID: 10464706]
  39. Biochemistry. 1999 Sep 7;38(36):11711-21 [PMID: 10512627]
  40. Curr Opin Immunol. 1992 Oct;4(5):613-8 [PMID: 1418728]
  41. Biochemistry. 1997 Jun 3;36(22):6564-70 [PMID: 9184135]
  42. Immunol Lett. 2002 Aug 1;83(1):13-20 [PMID: 12057850]
  43. J Exp Med. 2002 Jul 1;196(1):129-34 [PMID: 12093877]
  44. Cancer Res. 2002 Aug 1;62(15):4390-7 [PMID: 12154045]
  45. Curr Gene Ther. 2002 Sep;2(3):379-92 [PMID: 12189722]
  46. Leukemia. 2002 Sep;16(9):1637-44 [PMID: 12200675]
  47. Cancer Immunol Immunother. 2002 Nov;51(9):505-12 [PMID: 12357322]
  48. Chest. 2002 Oct;122(4):1421-7 [PMID: 12377874]
  49. Mol Ther. 2002 Oct;6(4):528-36 [PMID: 12377195]
  50. Br J Haematol. 2002 Nov;119(2):425-31 [PMID: 12406081]
  51. Nat Immunol. 2002 Nov;3(11):991-8 [PMID: 12407406]
  52. Mol Ther. 2002 Nov;6(5):627-36 [PMID: 12409261]
  53. Cancer Gene Ther. 2002 Dec;9(12):1043-55 [PMID: 12522443]
  54. Vaccine. 2003 Jan 30;21(7-8):753-60 [PMID: 12531355]
  55. Cancer Immunol Immunother. 2003 Feb;52(2):67-79 [PMID: 12594570]
  56. J Immunol. 2003 Mar 1;170(5):2456-60 [PMID: 12594270]
  57. J Immunol. 2004 Feb 1;172(3):1508-14 [PMID: 14734728]
  58. Carcinogenesis. 2004 Mar;25(3):405-11 [PMID: 14633660]
  59. Transplantation. 1974 Jan 1;17(1):135-6 [PMID: 4809199]
  60. Science. 1974 Feb 8;183(4124):534-6 [PMID: 4588620]
  61. Acta Pathol Microbiol Scand B Microbiol Immunol. 1974 Feb;82(1):99-106 [PMID: 4597815]
  62. J Reticuloendothel Soc. 1975 Jan;17(1):1-9 [PMID: 1089790]
  63. J Natl Cancer Inst. 1979 Feb;62(2):353-8 [PMID: 283266]
  64. Adv Cancer Res. 1979;29:45-125 [PMID: 382778]
  65. J Immunol. 1985 Nov;135(5):3596-603 [PMID: 3930610]
  66. Eur J Cell Biol. 1995 Oct;68(2):143-58 [PMID: 8575461]
  67. Lab Invest. 1996 Jan;74(1):43-7 [PMID: 8569196]
  68. Transplantation. 1996 Jan 27;61(2):274-8 [PMID: 8600636]
  69. Cancer. 1996 Apr 1;77(7):1303-10 [PMID: 8608507]
  70. Science. 1996 Oct 25;274(5287):610-4 [PMID: 8849452]
  71. Nat Genet. 1996 Dec;14(4):457-60 [PMID: 8944026]
  72. APMIS. 1996 Sep;104(9):629-39 [PMID: 8972687]
  73. Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2150-5 [PMID: 9122163]
  74. Genomics. 1997 Mar 1;40(2):222-33 [PMID: 9119388]
  75. Nat Genet. 1997 Apr;15 Spec No:415-6 [PMID: 9140408]
  76. Scand J Immunol. 1997 May;45(5):463-70 [PMID: 9160088]
  77. Biochem J. 1997 Jun 1;324 ( Pt 2):611-7 [PMID: 9182725]
  78. Eur J Cancer. 1992;29A(1):69-75 [PMID: 1445749]
  79. Cell. 1992 Dec 24;71(7):1093-102 [PMID: 1335364]
  80. Science. 1993 Jan 15;259(5093):368-70 [PMID: 7678351]
  81. Genes Dev. 1992 Dec;6(12B):2502-12 [PMID: 1340465]
  82. J Immunol. 2002 May 15;168(10):4864-70 [PMID: 11994435]
  83. Leuk Res. 2002 Jun;26(6):577-90 [PMID: 12007506]
  84. J Immunol. 2002 Jun 1;168(11):5491-8 [PMID: 12023343]

Grants

  1. R01 CA100223/NCI NIH HHS
  2. R01 CA100223-01A1/NCI NIH HHS

MeSH Term

Adjuvants, Immunologic
Animals
CD8-Positive T-Lymphocytes
Carcinoma
Female
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Immunity, Cellular
Interleukin-12
Lymphocyte Activation
Mammary Neoplasms, Experimental
Mice
Mice, Inbred BALB C
Neoplasm Transplantation
Oligonucleotide Array Sequence Analysis

Chemicals

Adjuvants, Immunologic
Interleukin-12
Journal Article Research Support, Non-U.S. Gov't

Word Cloud

Created with Highcharts 10.0.0IL-12expressionCTLresponsesgeneimmuneIL-12-inducedcytotoxicdevelopmentmolecularprofilingCD8+TmousemammarytumorregressionactivationInterleukin-12criticalcytokinerepresentinglinkcellularhumoralbrancheshostdefenseapparatuslymphocytecentralmechanismintracellularinfectiousagentswellmalignantgrowthHoweverbasistumor-specificmediatedremainspoorlydefinedstudyaddressedissuecomprehensivemannerprobeanti-tumorglobalmRNAcellstransplantablesyngeneiccarcinomamodeltreatedrecombinantstronginducedtreatmentintrospectiondifferentialearlystageIL-12-initiatedrevealsinterestinggenespathwaysmayaccountmarkedlikelyproviderichsourcepotentialtargetsresearcheffectivetherapeuticmodalitiesGlobalinterleukin-12-inducedlymphocytesCarcinoma

Similar Articles

Cited By